Shield Therapeutics Faces Appeal from Teva over Ferracru Patent
03 Juin 2019 - 9:27AM
Dow Jones News
By Adam Clark
Shield Therapeutics PLC (STX.LN) said Monday that Teva
Pharmaceutical Industries Ltd. (TEVA) has filed a notice of appeal
against the recent grant of a European patent for Shield's Feraccru
iron-deficiency treatment.
Shield said Teva opposed its patent covering a "process for
preparing an iron hydroxypyrone."
No data has been set for the hearing. Shield said it will defend
its intellectual property.
Write to Adam Clark at adam.clark@dowjones.com;
@AdamDowJones
(END) Dow Jones Newswires
June 03, 2019 03:12 ET (07:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
